Time traveling and unraveling the $EBS’s turbulent yet progresive year.
Emergent BioSolutions ($EBS) saw significant growth as it gained FDA approval for its NARCAN nasal spray, crucial in fighting America’s opioid crisis. The company later faced severe financial strain due to heavy debt, but strategic leadership changes, including the hiring of biotech veteran Joseph C. Papa as CEO, set it on a path of transformation. Through workforce reductions, asset sales, and a refinance of its debt, $EBS has positioned itself as a critical player in pandemic preparedness, with its smallpox and monkeypox vaccines boosting revenue and stock performance.